期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
晚期非小细胞肺癌免疫治疗疗效及其影响因素研究 被引量:1
1
作者 庄茜茹 黄文强 +2 位作者 何志江 高颜凤 杨子恒 《中国实用医药》 2023年第5期30-34,共5页
目的通过分析不同细胞程序性死亡受体配体1(PD-L1)表达水平晚期非小细胞肺癌患者的免疫治疗疗效,探讨其可能的影响因素。方法43例晚期非小细胞肺癌患者,根据PD-L1表达水平不同分为阴性组(18例)、1%~49%组(13例)、≥50%组(12例)。三组患... 目的通过分析不同细胞程序性死亡受体配体1(PD-L1)表达水平晚期非小细胞肺癌患者的免疫治疗疗效,探讨其可能的影响因素。方法43例晚期非小细胞肺癌患者,根据PD-L1表达水平不同分为阴性组(18例)、1%~49%组(13例)、≥50%组(12例)。三组患者均行免疫治疗。比较三组患者的临床资料;统计患者的总生存期(OS)、无进展生存期(PFS);分析患者免疫治疗疗效的影响因素。结果三组患者的年龄、性别、体力活动状态(PS)评分、分期、脑转移、肾上腺转移、其他位置转移、病理类型比较差异无统计学意义(P>0.05);阴性组有吸烟史17例(94.44%),1%~49%组12例(92.31%),≥50%组5例(41.67%);阴性组驱动基因突变1例(5.56%),1%~49%组5例(38.46%),≥50%组0例(0);阴性组骨转移6例(33.33%),1%~49%组0例(0),≥50%组5例(41.67%)。三组患者的吸烟史、驱动基因突变、骨转移情况比较差异具有统计学意义(P<0.05)。在OS方面,单因素分析显示:PD-L1表达水平、年龄、驱动基因突变以及分期和患者的OS有关(P<0.05);多因素分析显示:PD-L1表达水平、年龄、驱动基因突变以及分期是患者OS的独立影响因素(P<0.05)。在PFS方面,单因素分析显示,PD-L1表达水平、年龄、驱动基因突变和患者的PFS有关(P<0.05);多因素分析显示:PD-L1表达水平、年龄是患者PFS的独立影响因素(P<0.05)。结论晚期非小细胞肺癌PD-L1表达水平与患者预后相关,PD-L1表达水平、年龄是影响患者PFS的独立影响因素,而PD-L1表达水平、年龄、驱动基因突变以及分期是影响患者OS的独立影响因素。 展开更多
关键词 晚期非小细胞肺癌 免疫治疗疗效 影响因素
下载PDF
非小细胞肺癌免疫治疗的影像学研究进展 被引量:5
2
作者 田琪(综述) 冯峰(审校) 《放射学实践》 CSCD 北大核心 2023年第2期230-234,共5页
非小细胞肺癌(NSCLC)免疫治疗是近年来的研究热点,传统的影像技术主要从宏观层面对肿瘤进行监测,已经无法完全满足临床诊断与治疗的需求。影像组学能从分子层面挖掘肿瘤生物学特性,为患者免疫治疗的疗效评价及预后预测提供了新的方法。... 非小细胞肺癌(NSCLC)免疫治疗是近年来的研究热点,传统的影像技术主要从宏观层面对肿瘤进行监测,已经无法完全满足临床诊断与治疗的需求。影像组学能从分子层面挖掘肿瘤生物学特性,为患者免疫治疗的疗效评价及预后预测提供了新的方法。笔者围绕影像学预测NSCLC免疫检查点标志物及疗效和预后进行综述。 展开更多
关键词 非小细胞肺癌 免疫治疗 影像学 免疫检查点标志物 免疫治疗疗效评价
下载PDF
Synthetic immunity to break down the bottleneck of cancer immunotherapy 被引量:2
3
作者 陈志英 马飞 +1 位作者 黄海亮 何成宜 《Science Bulletin》 SCIE EI CAS CSCD 2015年第11期977-985,I0007,共10页
As a result of recent breakthroughs in cancer immunotherapies, unprecedented and durable remission, and even cure, has been reported in some patients. Importantly, this progress has been achieved, not by the induction... As a result of recent breakthroughs in cancer immunotherapies, unprecedented and durable remission, and even cure, has been reported in some patients. Importantly, this progress has been achieved, not by the induction of immunity, but by the delivery of immunity in the form of engineered antibodies (cAbs) or effector T cells. However, these single-target technologies have failed to result in a therapeutic effect in some patients, and evidence suggests that further advances depend on an effective strategy for coping with cancer heterogeneity and dynamics. A synthetic immunity (SI) strategy is proposed to achieve this goal. The fundamental basis of SI involves the generation of a panel of cAbs and antibody-retargeted CTLs designed to destroy all cell lineages of a cancer with high specificity. This goal can be achieved only when the composition of the cAbs is determined using a systematic approach, i.e., selecting the antigens targeted by the cAbs based on an epitope-tree illustrating the clonal antigen architecture of the cancer. Integration of technologies that increase the epitope breadth, cAb affinity and T cell activity will further enhance the efficacy of SI. Using DNA vectors to express the eAbs will be a safe, effective and affordable solution. 展开更多
关键词 Cancer immunotherapy Synthetic immunity Non-viral vector Engineered antibody Bispecific antibody Retargeting T cell
原文传递
Chest wall abscess due to Prevotella bivia 被引量:1
4
作者 Gwo-jong HSU Cheng-ren CHEN +1 位作者 Mei-chu LAI Shi-ping LUH 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2009年第3期233-236,共4页
Prevotella bivia is associated with pelvic inflammatory disease. A 77-year-old man developed a rapidly growing chest wall abscess due to P. bivia within days. He underwent surgical resection of the infected area; his ... Prevotella bivia is associated with pelvic inflammatory disease. A 77-year-old man developed a rapidly growing chest wall abscess due to P. bivia within days. He underwent surgical resection of the infected area; his postoperative course was uneventful. This is the first case of chest wall abscess due to P. bivia infection. Its correct diagnosis cannot be underestimated because fulminant infections can occur in aged or immunocompromised patients if treated incorrectly. Prompt,appropriate surgical management,and antibiotic therapy affect treatment outcome. 展开更多
关键词 Prevotella bivia Chest wall abscess RESECTION RECONSTRUCTION
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部